I-Mab added to Nasdaq Biotechnology Index

Daily Record Staff//December 14, 2020//

Listen to this article

I-Mab, a clinical stage biopharmaceutical company with U.S. offices in Gaitherburg and committed to the discovery, development and commercialization of novel biologics, Monday announced that I-Mab’s American Depositary Shares (ADS) have been selected for inclusion in the NASDAQ Biotechnology Index, based on the results of the annual reconstitution of the index announced by Nasdaq Dec. 11. The inclusion will become effective prior to the U.S. market opening Dec. 21.

Launched in 1993, the NBI is a modified market-cap weighted index designed to track the performance of a set of securities listed on The Nasdaq Stock Market that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. The NBI, as a major global biotech equity index, is widely followed and tracked by many investors and Exchange Traded Funds products worldwide.

The NBI is reconstituted annually in December in accordance with a set of eligibility criteria including minimum market capitalization and average daily trading volume. The index currently has 198 securities as its components.